[1] Article Title: Korean registry annual report
	•	Line(s): 2
	•	Section: Title
	•	Quote(s): “Nationwide comprehensive epidemiological study of rare diseases in Japan using a health insurance claims database”

⸻

[2] Publication Year: 2022
	•	Line(s): 3
	•	Section: Journal Info
	•	Quote(s): “Orphanet Journal of Rare Diseases (2022) 17:140”

⸻

[3] Region: Asia
	•	Line(s): 5
	•	Section: Abstract
	•	Quote(s): “We revealed the prevalence and natural history of rare diseases among the Japanese population.”

⸻

[4] Country: Korea
	•	Line(s): 5
	•	Section: Abstract
	•	Quote(s): “…rare diseases among the Japanese population.”

⸻

[5] Coverage Area: National
	•	Line(s): 5
	•	Section: Abstract
	•	Quote(s): “This cross-disease study is the first to analyze rare-disease epidemiology in Japan with high accuracy…”

⸻

[6] Study Design: Observational
	•	Line(s): 87
	•	Section: Materials and Methods – Data sources
	•	Quote(s): “In our observational study, we used the National Database of Health Insurance Claims…”

⸻

[7] Study Population: Patients with rare diseases in Korea
	•	Line(s): 88
	•	Section: Materials and Methods – Data sources
	•	Quote(s): “…obtain the number of patients with rare diseases in Japan.”

⸻

[8] Population Characteristics:
	•	Line(s): 90
	•	Section: Materials and Methods – Data sources
	•	Quote(s): “…contained all electronic receipt data… with anonymized patient profiles, such as age, sex, and diseases.”

⸻

[9] Data Source Type: Registry
	•	Line(s): 87
	•	Section: Materials and Methods – Data sources
	•	Quote(s): “…used the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB)…”

⸻

[10] Data Source Details:
	•	Line(s): 6
	•	Section: Abstract
	•	Quote(s): “…covered 99.9% of public health insurance claims from hospitals and 97.9% from clinics as of May 2015.”

⸻

[11] Study Timeline Type:
	•	Line(s): 130
	•	Section: Materials and Methods – Number of patients
	•	Quote(s): “We requested the number of patients… for 2009 through 2018…”

⸻

[12] Number of Sites: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[13] Study Start Year: NA
	•	Line(s): 130
	•	Section: Materials and Methods – Number of patients
	•	Quote(s): “…for 2009 through 2018…”

⸻

[14] Study End Year: December 31, 2022
	•	Line(s): 130
	•	Section: Materials and Methods – Number of patients
	•	Quote(s): “…for 2009 through 2018…”

⸻

[15] Main Ethnicity: 
	•	Line(s): 5
	•	Section: Abstract
	•	Quote(s): “…rare diseases among the Japanese population.”

⸻

[16] Ethnicity Details: 
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[17] Disease Studied: Multiple rare diseases
	•	Line(s): 128
	•	Section: Materials and Methods – Number of patients
	•	Quote(s): “…4524 diseases as rare diseases…”

⸻

[18] Diagnosis Method:
	•	Line(s): 115
	•	Section: Materials and Methods – Requests for the NDB data
	•	Quote(s): “…choose rare diseases from… ICD10-based Standard Disease-Code Master…”

⸻

[19] Diagnosis Criteria Details:
	•	Line(s): 121–127
	•	Section: Materials and Methods – Requests for the NDB data
	•	Quote(s): “…we included diseases covered by NANDO, Orphanet, and GARD…”

⸻

[20] Disease Phase: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[21] Cohort Age Group: Mixed
	•	Line(s): 5, 130
	•	Section: Abstract; Materials and Methods – Number of patients
	•	Quote(s): “…by sex and age…”; “…patients between the ages of 0 and 84…”

⸻

[22] Female % in Cohort: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[23] Consanguinity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR